Zivo Bioscience Inc (PK:ZIVO)
Business Focus: Special Foods & Welbeing Products
Feb 07, 2024 04:54 pm ET
ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics.
Jan 29, 2024 08:00 am ET
ZIVO Bioscience Announces Uplisting to OTCQB Market
Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces it has uplisted the trading of shares of its common stock from the OTC® Pink Market to the OTCQB® Venture Market (OTCQB), effective as of the opening of trading on Friday, January 26, 2024. Following this uplisting, ZIVO Bioscience continues to trade under the ticker symbol “ZIVO” and warrants continue to trade under the ticker symbol “ZIVOW”.
Oct 30, 2023 08:30 am ET
ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day study to further validate the efficacy of its novel immune-modulating treatment for coccidiosis in broiler chickens.
Oct 26, 2023 08:30 am ET
ZIVO Bioscience Announces Reverse Stock Split
Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that the Board of Directors of the Company approved a 1-for-6 reverse stock split (the “Reverse Stock Split”) of its shares of common stock, par value $0.001 (the “Common Stock”) effective at 5:00 p.m. ET on October 26, 2023 (the “Effective Time”). The Company’s Common Stock will begin trading on a split-adjusted basis on October 27, 2023 and will continue to trade on the Nasdaq
Oct 03, 2023 08:30 am ET
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that management will...
Sep 21, 2023 09:35 am ET
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand...
Sep 19, 2023 04:15 pm ET
Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an independent veterinary research provider. The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens examined multiple product lots as well as multiple product test concentrations and produced statistically significant
Jul 26, 2023 04:15 pm ET
ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the commercialization of its proprietary algal biomass as a food or food ingredient.
Jun 30, 2023 01:55 pm ET
ZIVO Bioscience Announces Pricing of $4.0 Million Registered Direct Offering Priced At-The-Market
Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,498,130 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue and sell to the investor Series A warrants to purchase up to
May 30, 2023 08:45 am ET
ZIVO’s GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as a Human Food Ingredient
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced it has received an updated dossier from an independent scientific review panel reconfirming the Company’s “Generally Recognized As Safe” (GRAS) designation for its proprietary algal biomass to be marketed and used as an ingredient in a defined range of foods and beverages for human consumption.
Apr 05, 2023 04:05 pm ET
ZIVO Bioscience Receives $1 Million Bridge Financing
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced a $1 million unsecured six-month loan from its Chairman, Chief Executive Officer, and President, John Payne. The loan carries 10% simple interest, may be prepaid without penalty, is extendable for an additional six months and includes warrants to purchase 390,000 shares of ZIVO common stock with a strike price of $2.91 per share. More information on the loan and
Feb 10, 2023 04:37 pm ET
ZIVO Bioscience Announces Results of Study with its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis trial in broiler chickens. The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens produced questionable results due to a high disease burden among tested chickens.
Oct 24, 2022 04:15 pm ET
ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC (“ZIVOLife”), a newly formed wholly-owned subsidiary, to streamline the Company’s corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company’s proprietary algae biomass.
Sep 23, 2022 08:00 am ET
ZIVO Bioscience CEO Issues Letter to Shareholders
Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today issued the following letter to shareholders from its Chairman, President and Chief Executive Officer, John Payne.
Aug 10, 2022 04:15 pm ET
ZIVO Reports that USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces receipt of a letter from the U.S. Department of Agriculture’s (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens.
Jun 27, 2022 08:00 am ET
Zivo Bioscience Joins Russell Microcap® Index
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that, effective today, June 27, 2022, it has joined the Russell Microcap® Index (^RUMIC) as a result of the 2022 Russell indexes annual reconstitution.
Apr 25, 2022 04:05 pm ET
Zivo Bioscience Regains Compliance Following Receipt of Noncompliance Notice from Nasdaq
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that it received a Notice from Nasdaq that the Company has regained compliance of Nasdaq Listing Rule 5250(c)(1).
Jan 10, 2022 05:00 pm ET
ZIVO Bioscience Names Chairman John B. Payne as President and CEO
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that Chairman of the Board John B. Payne has been named President and Chief Executive Officer of the Company. Mr. Payne succeeds Andrew A. Dahl.
Oct 06, 2021 10:09 am ET
Zivo Bioscience, Inc. to Participate in the Global AgTech Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on October 14, 2021 at 10 A.M. EDT
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary...
Oct 05, 2021 12:56 pm ET
Weblink Instructions for the Annual Meeting of Shareholders of Zivo Bioscience, Inc.
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary...
Aug 17, 2021 04:05 pm ET
Zivo Bioscience, Inc. Issues Letter to Shareholders
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary...
Aug 11, 2021 08:00 am ET
Zivo Bioscience to Present at Two Upcoming August Conferences
Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today announced...
Aug 11, 2021 07:00 am ET
ZIVO Bioscience to Present at the Q3 Virtual Investor Summit
Keego Harbor, Michigan--(Newsfile Corp. - August 11, 2021) - ZIVO Bioscience (NASDAQ: ZIVO) today announced that Andrew Dahl will be attending the Q3 Virtual Investor Summit.
Jul 02, 2021 08:00 am ET
Zivo Bioscience, Inc. Announces Closing of Underwriters’ Partial Exercise of Over-Allotment Option in Connection with its Previously Announced Public Offering
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary...
Jun 02, 2021 09:30 am ET
ZIVO Bioscience to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
ZIVO Bioscience, Inc. (NASDAQ:ZIVO), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional bioproduct candidates originally derived from proprietary algal cultures, today announced...
Jun 02, 2021 09:05 am ET
Zivo Bioscience, Inc. Announces Closing of Upsized $13.8 Million Public Offering and Uplisting to Nasdaq
Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary...
May 27, 2021 08:42 pm ET
Zivo Bioscience, Inc. Announces Pricing of Upsized $13.8 Million Public Offering and Up-listing to Nasdaq
Zivo Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, today announced the pricing of...
Apr 26, 2021 12:06 pm ET
ZIVO Bioscience Announces US Patent Office Notice of Allowance for Administration of Proprietary Algal Biomass to Support Immune Health
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, announces today the US Patent...
Mar 11, 2021 12:25 pm ET
ZIVO Bioscience to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and additive product candidates originally derived from proprietary algal cultures, announces that CEO Andrew A. Dahl...
Jan 11, 2021 02:50 pm ET
ZIVO Bioscience Successfully Confirms Poultry Growth Promotion and Feed Conversion Ratio Improvements in Typical Production Environments
KEEGO HARBOR, MI / ACCESSWIRE / January 11, 2021 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic/additive product candidates originally derived from proprietary algal cultures, announces today that in its recent analysis of two poultry studies performed at separate research facilities, ZIVO product candidates provided statistically significant feed conversion benefits in healthy broiler flocks exposed to pathogens present in litter from previous flocks, emulating exposure that may occur in a typ
Jan 07, 2021 04:35 pm ET
Zivo Bioscience Names Keith R. Marchiando as Chief Financial Officer
KEEGO HARBOR, MI / ACCESSWIRE / January 7, 2021 / ZIVO Bioscience, Inc. (OTCMQB:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, food and feed additive products announced today that Keith R. Marchiando joined the Company's as Chief Financial Officer, Treasurer, and Secretary, effective January 1, 2021.
Jul 13, 2020 08:00 am ET
Zivo Bioscience Releases Positive Results From Recent Poultry Trial
KEEGO HARBOR, MI / ACCESSWIRE / July 13, 2020 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and nutritional products derived from its proprietary algal cultures, announces today that results from its 15th consecutive poultry study confirm prior study results and offer new insights into the health benefits of its products.
Jun 09, 2020 08:30 am ET
ZIVO Bioscience Receives Notice of Allowance for Cytokine Modulation Patent Application From US Patent Office, Commences Bioproduct Scaleup
KEEGO HARBOR, MI / ACCESSWIRE / June 9, 2020 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and nutritional products derived from its proprietary algal cultures, announces today that the U.S. Patent and Trademark Office issued a Notice of Allowance for U.S. Patent application "Compounds and Methods for Affecting Cytokines" (Application Serial No. 16/273,794). A Notice of Allowance precedes the formal issuance of a U.S. patent, which is expected shortly.
Mar 30, 2020 11:20 am ET
ZIVO Bioscience Appoints Industry Veterans To Join Senior Management Team
KEEGO HARBOR, MI / ACCESSWIRE / March 30, 2020 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal cultures, is pleased to announce today the addition of Christine O'Neil and Dr. David Lafond to its leadership team. Christine and Dave bring to the organization executive-level experience in the food, supplement, and pet food industry and will be responsible for building a health and wellness business for the Company.
Mar 18, 2020 09:55 am ET
ZIVO Bioscience Announces Impressive Long-Term Benefits for Broiler Poultry Nutrition and Growth Promotion
KEEGO HARBOR, MI / ACCESSWIRE / March 18, 2020 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal cultures, announces today additional results from recent poultry gut health studies conducted in the last quarter of 2019. The findings indicate that beneficial nutrition and growth promotion effects of the Company's dried algal biomass poultry feed ingredient were observed throughout the entire 42-day broiler grow period even when the ZIVO ingredient was included in
Feb 06, 2020 08:00 am ET
ZIVO Bioscience Announces Impressive Results for Poultry Gut Health Studies Conducted in Q3/Q4 2019 Utilizing Proprietary Algal Biomass as Feed Ingredient
KEEGO HARBOR, MI / ACCESSWIRE / February 6, 2020 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal cultures, announces today that several poultry gut health studies conducted in the last two quarters of 2019 have yielded statistically significant and repeatedly successful results across five (5) different research studies performed at three (3) independent research facilities. After receiving and analyzing reports from contract research organizations and university r
Dec 18, 2019 09:20 am ET
Zivo Bioscience Announces Patent Filings for a Novel, Proprietary, Immune-Modulating/Anti-Inflammatory Molecular Complex
KEEGO HARBOR, MI / ACCESSWIRE / December 18, 2019 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the commercialization of therapeutic and nutritional products derived from its proprietary algal cultures, announces today that the Company has filed patent applications to protect research and processes relating to immune modulation and inflammatory response in humans and animals. The research findings describe a novel polysaccharide molecular complex that has been optimized to inhibit inflammatory cytokine production, among other related modes of
Oct 08, 2019 11:05 am ET
Wellmetrix and DSM Announce Research Partnership to Assess Diagnostic Platform for Personalized Nutrition
KEEGO HARBOR, MI / ACCESSWIRE / October 8, 2019 / Personal health testing developer Wellmetrix and Royal DSM, a purpose-led, global science-based company active in Nutrition, Health and Sustainable Living, have announced a research partnership to explore the use of Wellmetrix's diagnostic platform to perform non-invasive and point-of-need measurements of key health biomarkers as part of a nutrition intervention using combinations of DSM's nutritional solutions.
Apr 29, 2019 09:20 am ET
ZIVO To Hold Its Annual Meeting May 1, 2019 at the Detroit Athletic Club
KEEGO HARBOR, MI / ACCESSWIRE / April 29, 2019 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a Michigan-based biotech/agtech R&D company will hold the Annual Meeting of shareholders of Zivo Bioscience, Inc. on May 1, 2019 at The Detroit Athletic Club, 241 Madison Street, Detroit, Michigan 48226, on Wednesday, May 1, 2019 at 10:00 a.m. local time. The Definitive Proxy Statement announcing the Annual Meeting was filed with the United States Securities and Exchange Commission on March 25, 2019.
Apr 08, 2019 08:00 am ET
Zivo Commences Third Dairy Cow Mastitis Trial to Validate Efficacy and Method of Administration for a New Pathogen Target
KEEGO HARBOR, MI / ACCESSWIRE / April 8, 2019 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a Michigan-based biotech/agtech R&D company has commenced a third in vivo dairy cow mastitis study to validate its bioactive compounds in combating a specific infective pathogen via a specific method of administration. Neither the pathogen nor the method of administration can be disclosed at this time, other than to characterize the pathogen as a widespread animal health issue worldwide.
Jan 22, 2019 08:00 am ET
Zivo Subsidiary Wellmetrix LLC Announces Milestone Patent
KEEGO HARBOR, MI / ACCESSWIRE / January 22, 2019 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) subsidiary WellMetrix, LLC presented its latest technology to analysts and investors at the Digital Medicine and Medtech Showcase held during the annual JPMorgan global healthcare conference in San Francisco January 6 - 10, 2019. The conference drew thousands of health industry insiders from around the world.
Dec 19, 2018 09:55 am ET
ZIVO Nutritional Efficacy Study for Poultry is Successful, Confirms Production Methods and Health Benefits
KEEGO HARBOR, MI / ACCESSWIRE / December 19, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that preliminary data analysis from its most recent poultry nutritional efficacy study show positive results that confirm the successes of previous poultry efficacy studies conducted in partnership with NutriQuest, a global innovator in animal nutrition.
Dec 03, 2018 08:10 am ET
Zivo Bioscience Executes Letter Of Intent With Dr. Steven K. Grekin/Grekin Laboratories To Field Exclusive Line Of Beauty-From-Within Nutraceuticals
KEEGO HARBOR, MI / ACCESSWIRE / December 3, 2018 / ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that company principals have executed a letter of intent with Dr. Steven K. Grekin, an innovator and pioneer in dermatological practices focused on anti-aging and skin health. The letter of intent describes a joint effort to develop, test and launch an exclusive line of products that feature the Company's proprietary algae strain, which has re
Nov 12, 2018 09:00 pm ET
Zivo Claims Gras Status for its Proprietary Algal Biomass, Allowing Immediate Marketing of its Premiere Product as a Human Food Ingredient
KEEGO HARBOR, MI / ACCESSWIRE / November 12, 2018 / ZIVO Bioscience, Inc. (OTCMKTS: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that it has received notice from an independent scientific review panel that ZIVO has satisfied the safety and process requirements to affirm GRAS status for its proprietary Kalgae™ branded dried algal biomass. GRAS refers to FDA designation Generally Recognized As Safe and allows the Company to market its p
Oct 30, 2018 06:15 pm ET
ZIVO Bioscience, Inc. Annual Shareholder Meeting and Conference Call Slated for November 7, 2018 in Detroit, Michigan
KEEGO HARBOR, MI / ACCESSWIRE / October 30, 2018 / ZIVO Bioscience, Inc., (OTCQB: ZIVO) a Michigan-based biotech firm, invites shareholders, analysts and partners to its annual shareholder meeting on Wednesday, November 7, 2018, beginning at 10:00AM EDT. The event will be held at the Westin Hotel located within the Detroit Metropolitan Airport (DTW) Midfield Terminal building, in the meeting room levels below the main atrium. The Company's management will share its progress on various resea
Sep 20, 2018 08:00 am ET
Zivo Safety Study Accepted for Publication in Toxicology Journal, Allows Company to Proceed with GRAS Review Panel for Market Approval
KEEGO HARBOR, MI / ACCESSWIRE / September 20, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) abiotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that Toxicology Reports, a peer-reviewed scientific journal, has accepted the Company's safety testing manuscript for publication. This is a necessary step in meeting compliance requirements for GRAS (Generally Recognized As Safe) affirmation and subsequent market entry.With the acceptance in hand, ZIVO can now move forward with a GRA
Jun 21, 2018 08:00 am ET
Food & Beverage/Consumer Packaged Goods Industry Veteran Joins ZIVO Bioscience, Inc. as VP - Global Operations
KEEGO HARBOR, MI / ACCESSWIRE / June 21, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from its proprietary algal strains, announces today that Ronald C. Costephens has joined the Company as Vice-President- Global Operations. Mr. Costephens is charged with building out a global supply chain and an organization to help transition ZIVO from an R&D entity into an operating enterprise that will engage not only in the licensing of its intellectual property portfolio, but
Jun 13, 2018 07:45 am ET
Zivo Bioscience, Inc. Reports Positive Results for Synthetic Therapeutic Candidates in a Pilot Experiment as Part of Bovine Mastitis Drug Discovery Program
KEEGO HARBOR, MI / ACCESSWIRE / June 13, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from its proprietary algal strains, announces today that it has received positive results from a discovery-stage efficacy pilot experiment designed to test the efficacy of certain lead compounds against well-known bacterial infections that cause bovine mastitis. This latest experiment builds on previous in vitro research and an in vivo efficacy study which showed that bioactive compo
May 01, 2018 12:45 pm ET
Zivo Bioscience, Inc. Announces Results For 90-Day Safety & Toxicology Study, Clearing the Way to Regulatory Compliance For Dried Algae Biomass Product
KEEGO HARBOR, MI / ACCESSWIRE / May 1, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today that a final report for safety/toxicology tests performed late last year was formally issued last week by Product Safety Labs, an independent laboratory based in Dayton, New Jersey. The study is part of the documentation utilized to meet "Generally Recognized As Safe" (GRAS) compliance standards set forth by the
Apr 24, 2018 01:10 pm ET
Zivo Bioscience, Inc. Executes Letters of Intent with India-Based Algae Producers, Ships Algal Starter Inoculum to Growers in Taiwan
KEEGO HARBOR, MI / ACCESSWIRE / April 24, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today that Wellisen Nutraceuticals and Sanat Products Ltd., both established algae producers located in the Indian subcontinent's southernmost region, have executed letters of intent to produce the ZIVO algae strain exclusively for ZIVO under a license from ZIVO. The Company is in the process of transferring its proprietary strain to laborato
Mar 29, 2018 08:00 am ET
ZIVO Bioscience, Inc. Welcomes New Vice-President of Research & Development
KEEGO HARBOR, MI / ACCESSWIRE / March 29, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today William P. Pfund has joined the Company as its new Vice-President of Research & Development. Mr. Pfund will manage overall research objectives, compliance initiatives and help transition the Company's ongoing R&D into marketable products and licenses. Dr. Amy Steffek will continue in her role as Director, Research & Developm
Feb 12, 2018 06:09 pm ET
Largest Shareholder of ZIVO Bioscience, Inc. to extend maturity date of its Convertible Debt
KEEGO HARBOR, Mich., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today its largest shareholder, HEP Investments,...
Feb 01, 2018 07:52 am ET
ZIVO Bioscience and Tianjin Norland Biotech Execute Letter of Intent to Produce ZIVO Algae Strain in China for International and Domestic Markets
KEEGO HARBOR, Mich., Feb. 01, 2018 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO), a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today the execution of a letter...
Jan 08, 2018 08:00 am ET
ZIVO Bioscience Subsidiary Wellmetris Selected to Present at Biotech Showcase During JPMorgan Healthcare Conference Jan 7-10 in San Francisco, CA
KEEGO HARBOR, Mich., Jan. 08, 2018 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO), a biotech/agtech R&D company, announced today that its WellMetris subsidiary will be presenting at the Biotech Showcase at the Hilton San Francisco Union Square hotel...
Nov 07, 2017 08:17 am ET
ZIVO Bioscience, Inc. Annual Shareholder Meeting and Conference Call Slated for November 8, 2017 in Detroit, Michigan
KEEGO HARBOR, Mich., Nov. 07, 2017 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc., (OTCQB:ZIVO) a Michigan-based biotech firm, invites shareholders, analysts and partners to its annual shareholder meeting on Wednesday, November 8, 2017, beginning at 10:00AM EST. The event...
Sep 11, 2017 08:00 am ET
ZIVO Bioscience, Inc. Kicks Off Final Phase of Bovine Mastitis Study
KEEGO HARBOR, Mich., Sept. 11, 2017 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today that it has commenced work on the final, primary phase of its discovery-stage bovine mastitis efficacy study. This latest efficacy trial is the final phase of a multi-phased validation effort that commenced in mid-2014. ZIVO and a global animal health company entered into an option/collaboration agreement in December of 2013 to determine if th...
Apr 26, 2017 04:36 pm ET
ZIVO Bioscience, Inc. Executes Definitive Agreement With NutriQuest, Commences Poultry Field Trial
KEEGO HARBOR, Mich., April 26, 2017 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a company dedicated to the development and commercialization of nutritional compounds and bioactive molecules derived from its proprietary algal strains, announces today that the Company has executed a definitive agreement with NutriQuest®, an innovative leader in animal health and nutrition solutions, to jointly test and develop animal nutrition products for livestock and poultry. The definitive agreement also grants NutriQuest a worldwide license to market the resulting products under its brand nam...
Mar 22, 2017 08:29 pm ET
ZIVO Bioscience, Inc. Debuts New Corporate Website, Shareholder Outreach
KEEGO HARBOR, Mich., March 22, 2017 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a company dedicated to the development and commercialization of nutritional compounds and bioactive molecules derived from its proprietary algal strains, announces that a new corporate website featuring the latest project news and investor information is up and running at http://www.zivobioscience.com/ and updates are planned to appear on a regular, monthly basis....
Dec 15, 2016 08:00 am ET
ZIVO Bioscience and NutriQuest Execute Agreement to Jointly Pursue New Feed and Feed Additive Solutions for Poultry and Swine Nutritional Applications
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a company dedicated to the development and commercialization of nutritional compounds and bioactive molecules derived from its proprietary algal strains, and NutriQuest LLC, an innovative leader in animal health and nutrition solutions, announced the execution of a Letter of Intent to jointly develop and test animal nutrition products derived from the proprietary ZIVO algae strain. Both firms have committed to enter into a definitive agreement that grants NutriQuest a worldwide license to market the products under its brand name. Product formulation and
Nov 29, 2016 01:27 pm ET
ZIVO Bioscience Granted New US Patent for Healthy Cholesterol Balance
ZIVO Bioscience, Inc. (OTCQB: ZIVO) announced today that it received notice of a fourth US patent issued on November 17, 2016 covering the novel cholesterol management properties of the bioactive components extracted from its proprietary algal culture.
Nov 17, 2016 08:08 am ET
ZIVO Bioscience Presents New Powdered Protein Product Concept at November 9 Annual Shareholders Meeting
ZIVO Bioscience, Inc. (OTCQB: ZIVO) unveiled a new, high-protein vegan power drink concept at the Company's annual shareholders meeting on November 9, 2016 in Detroit, Michigan.
Nov 07, 2016 04:30 pm ET
ZIVO Bioscience, Inc. Annual Shareholder Meeting and Conference Call Slated for November 9, 2016 in Detroit, Michigan
ZIVO Bioscience, Inc., (OTCQB: ZIVO) a Michigan-based biotech firm, invites shareholders, analysts and partners to its annual shareholder meeting on Wednesday, November 9, 2016, beginning at 10:00AM EST. The event will be held at the Westin Hotel located within the Detroit Metropolitan Airport (DTW) Midfield Terminal building, in the meeting room levels below the main atrium. The Company's management will share its progress on various research and product development efforts over the past year.
Nov 02, 2016 08:00 am ET
ZIVO Bioscience Increases Credit Line To $17.5 Million, Finds Early Success In $5 Million Capital Funding Initiative
ZIVO Bioscience, Inc. (OTCQB: ZIVO) announces today that from July 1, 2016 to date, the Company has received $2 million in new capital funding as part of its Q3/Q4 capital funding initiative. This brings the total of new funding to $3.25 million year to date. In related news, the ZIVO Board of Directors recently approved an increase in the available credit line from HEP Investments, LLC to $17.5 million. To accommodate this enhanced level of funding, a proxy measure has been placed before the shareholders to increase the authorized share base by 150 million shares to 450 million authorized
Sep 21, 2016 07:00 am ET
ZIVO Bioscience, Inc. Issues CEO Report for Q2/Q3 2016
ZIVO Bioscience, Inc. (OTCQB: ZIVO)
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.